Propeller Health added a second big pharma partner with its GlaxoSmithKline research and development deal to produce sensors for the company’s Ellipta dry powder inhaler, according to a company statement. It comes four months after the U.S. Food and Drug Administration cleared the Propeller’s remote monitoring platform for the inhaler for COPD and asthma applications and two years after Propeller began a partnership with Boehringer Ingelheim.
It is the latest in a series of pharma and digital health collaborations that have the potential to not only improve monitoring between routine checkups, but also transform clinical trials by making them more economical to carry out on a large scale.
Read Full Article »